GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
GILEAD SCIENCES, INC. (GILD) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $133.00 million as of 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2015-02-25
- 2014-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $133.00M.
- 2013-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $264.00M; Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed $263.76M.
- 2013-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $252.50M.
- 2013-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $222.50M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2014-12-31 | $133.00M 10-K · filed 2015-02-25 | |
| 2013-12-31 | $264.00M 10-K · filed 2015-02-25 | $263.76M 10-K · filed 2014-02-25 |
| 2013-09-30 | $252.50M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $222.50M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $211.08M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $205.00M 10-K · filed 2015-02-25 | $205.06M 10-K · filed 2013-02-27 |
| 2012-09-30 | $199.71M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $140.90M 10-Q · filed 2012-11-06 | |
| 2012-03-31 | $138.33M 10-Q · filed 2012-08-01 | |
| 2011-12-31 | $135.59M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $128.31M 10-Q · filed 2012-11-06 | |
| 2011-06-30 | $126.69M 10-Q · filed 2012-11-06 | |
| 2011-03-31 | $11.10M 10-Q · filed 2012-08-01 | |
| 2010-12-31 | $11.10M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |